Circio Holding Asa · OSL:CRNA
Circio Holding Asa — Targovax — LSX Nordic Congress 2022
23 slides from Circio Holding Asa's conference presentation, Sep 6, 2022
Slide 1: Activating the Patient's Immune System to Fight Cancer
ACTIVATING THE PATIENT’S IMMUNE SYSTEM TO FIGHT CANCER LSX Nordic Congress 2022 Dr. Erik Digman Wiklund, CEO OSE: TRVX
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This report contains certain forward-looking statements based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on the results of operations and the financial condition
Slide 3: Introduction
Introduction 2. Lead clinical program: ONCOS-102 3. Pipeline platform: Circular RNA 4. Outlook & strategy 3
Slide 4: The Immuno-Oncology Revolution
THE IMMUNO-ONCOLOGY REVOLUTION > 500,000 patients treated per year > 3,000 ongoing clinical trials > 40% of US cancer patients eligible > 10 approved products 4
Slide 5: First Generation Immuno-Oncology: Checkpoint Inhibitors
FIRST GENERATION IMMUNO-ONCOLOGY: CHECKPOINT INHIBITORS Cornerstone of current cancer treatment Deep and durable responses $30b annual sales globally 8 products approved to date, many more in development 5 SOURCE: GlobalData, Research&Markets
Slide 6: The Challenge: Make PD-1 Checkpoint Inhibitors Work for More Patients
THE CHALLENGE: MAKE PD-1 CHECKPOINT INHIBITORS WORK FOR 0-40% of treated patients respond MORE PATIENTS of responding >50% patients relapse 1 PD-1 checkpoint inhibitor monotherapy not sufficient 6 6
Slide 7: The Solution: Immune Activation by Targovax's Oncolytic Virotherapy ONCOS
THE SOLUTION: IMMUNE ACTIVATION BY TARGOVAX´S ONCOLYTIC VIROTHERAPY ONCOS Reverses immuno-suppressive defence mechanisms in the tumor Primes anti-cancer T-cell responses Delivers immune stimulatory payloads 7
Slide 8: Targovax Development Pipeline
TARGOVAX DEVELOPMENT PIPELINE Preclinical Clinical Product candidate Discovery IND- Phase 1 Phase 2 Phase 3 / 2022 Milestones enabling pivotal 4Q 2022 / 1Q 2023 PD-1 Refractory Melanoma Initiation of multi-cohort Re-challenge combination w/anti PD-1 phase 2 trial ONCOS-102 1H 2022 Mesothelioma Full
Slide 9: Lead clinical program: ONCOS-102
Lead clinical program: ONCOS-102 9
Slide 10: Targovax Development Pipeline
TARGOVAX DEVELOPMENT PIPELINE Preclinical Clinical Product candidate Discovery IND- Phase 1 Phase 2 Phase 3 / 2022 Milestones enabling pivotal 4Q 2022 / 1Q 2023 PD-1 Refractory Melanoma Initiation of multi-cohort Re-challenge combination w/anti PD-1 phase 2 trial ONCOS-102 1H 2022 Mesothelioma Full
Slide 11: ONCOS-102 Achieved a Highly Competitive ORR of 35% in PD-1 Refractory Melanoma Phase 1
ONCOS-102 ACHIEVED A HIGHLY COMPETITIVE ORR OF 35% IN A PD-1 REFRACTORY MELANOMA PHASE 1 CR PR 35 % ORR ONCOS-102 5% 30% (7/20 pts.) 37% ORR RP1 12% 25% (6/16 pts.) 35 % ORR BNT111 0% 35% (6/17 pts.) Anti-PD1 28 % ORR retreatment TAVO 8% 20% (15/50 pts.) 23 % ORR Vidutolimod 7% 16% (23/98 pts.) 15 %
Slide 12: Locally Delivered ONCOS-102 Generates Robust Systemic Activity
LOCALLY DELIVERED ONCOS-102 GENERATES ROBUST SYSTEMIC ACTIVITY Response in individual tumors % change from baseline; injected and non-injected target lesions Observed systemic (n=16) effect: (n=36) o 12 of 36 (33%) non-injected target lesions reduced in size o 8 of 15 (53%) patients had reduction in
Slide 13: ONCOS-102 Drives Strong and Consistent T-cell Infiltration in Responding Patients
ONCOS-102 DRIVES STRONG AND CONSISTENT T-CELL INFILTRATION IN RESPONDING PATIENTS CD8+ T-cell tumor infiltration CD8+ T-cell infiltration increased over time Tumor biopsy IHC, patient case example in patients with clinical benefit (CR+PR+SD) p = 0.01 Progression on 3x ONCOS-102 only 6x ONCOS-102 pem
Slide 14: Next Step ONCOS-102: Multi-cohort Phase 2 Trial with 2nd Gen CTLA-4 Combination
NEXT STEP ONCOS-102: MULTI-COHORT PHASE 2 TRIAL WITH 2ND GEN CTLA-4 CHECKPOINT INHIBITOR COMBINATION Part 1 – higher dose exploration run-in Part 2 – multi-cohort extension ONCOS-102 ONCOS-102 + 1 monotherapy 2 balstilimab o Expand to n=37 high dose1 high dose3 o Confirm safety Randomize o Select do
Slide 15: Phase 2 Trial Designed to Enable Future Out-licensing and Address Regulatory Requirements
THE PHASE 2 TRIAL IS DESIGNED TO ENABLE FUTURE OUT- LICENSING AND ADDRESS REGULATORY REQUIREMENTS ✓ Opportunity to achieve best-in-class data ✓ Differentiated combinations vs. competitors, with strong scientific and strategic rationale ✓ Design and size to enable licensing decisions for big pharma p
Slide 16: Pipeline platform: Circular RNA
Pipeline platform: Circular RNA 16
Slide 17: Emerging Circular RNA Technology Opens Novel Opportunities for Cancer Immunotherapy
EMERGING CIRCULAR RNA TECHNOLOGY OPENS NOVEL OPPORTUNITIES FOR CANCER IMMUNOTHERAPY The circRNA discoverers work for Targovax Dr. Thomas B. Hansen Dr. Erik D. Wiklund 17
Slide 18: circRNA Provides a Toolbox to Take Cancer Immunotherapy to the Next Level
CIRCRNA PROVIDES A TOOLBOX TO TAKE CANCER IMMUNOTHERAPY TO THE NEXT LEVEL Maximize payload expression Extra-cellular trafficking Circular RNA is resistant to exonuclease degradation, leading to vastly increased half-life Onco-microRNA sponging Immune response booster TLR PRR 18
Slide 19: Targovax' circRNA Platform Can Be Used in Multiple Biological Applications and Disease Areas
TARGOVAX´ CIRCRNA PLATFORM CAN BE USED IN MULTIPLE BIOLOGICAL APPLICATIONS AND DISEASE AREAS Targovax´ initial focus areas Cancer Intra-tumoral delivery of immunological immunotherapy payloads for TME remodulation Cancer gene Replacement of lost or silenced tumor therapy suppressor genes Potentially
Slide 20: Targovax Has a Unique Edge in the Emerging circRNA Space
TARGOVAX HAS A UNIQUE EDGE IN THE EMERGING CIRCRNA SPACE World-leading circRNA experts in-house with deep technical experience o Head of program is circRNA discoverer Dr. Thomas Hansen, the pionéer of early circRNA research with over 10 years experience in the field Clinically validated vector syste
Slide 21: Outlook & Strategy
Outlook & Strategy 21
Slide 22: Outlook: Multiple Paths to Value Creation
OUTLOOK: MULTIPLE PATHS TO VALUE CREATION Pillar Value creation strategy Out-license ONCOS-102 with results from phase 2 melanoma trial o Aim to “knock-it-out-of-the-park” with novel triple combination o Study designed and sized to be attractive for big pharma partners ONCOS-102 Create broad optiona
Slide 23: Questions?
QUESTIONS? Erik Digman Wiklund Lubor Gaal CEO CFO 23 erik.wiklund@targovax.com lubor.gaal@targovax.com